BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data From The Company's Ascites Phase 2 Trial Accepted For Presentation At AASLD – The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. (NASDAQ:BIVI) has announced that clinical safety data from its Phase 2 study on BIV201, a drug for the treatment of advanced liver disease and neurological disorders, will be presented at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023. The details of the presented data and conclusions will be announced once the presentations are made public at the conference.
October 26, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie's announcement of the presentation of its Phase 2 clinical safety data at a major conference could potentially increase investor interest and confidence in the company.
The announcement of the presentation of clinical safety data at a major conference is a positive development for BioVie. It indicates that the company's research is being recognized by the scientific community, which could increase investor confidence in the company's potential for success. However, the actual impact will depend on the details of the data and conclusions presented at the conference.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100